Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Inovio Pharmaceuticals, Inc. - Common Stock (NQ:INO)

1.390 +0.020 (+1.46%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Inovio Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
The Week Ahead In Biotech (May 8-14): Bausch Health Headlines Smid-Cap Earnings, Veru's Pre-EUA Meeting, Conference Presentations And More
Biotech stocks declined yet again in the week ending May 6, dragged lower by macroeconomic concerns following the Federal Reserve's 50-basis-point rate hike. The iShares Biotechnology ETF (NASDAQ:... 
Via Benzinga
7 F-Rated Penny Stocks Not Worth the Gamble
In a market with this kind of downside bias there are plenty of stocks that are on sale, so make sure to avoid bad penny stocks when buying. 
Via InvestorPlace
41 Stocks Moving In Wednesday's Mid-Day Session
Gainers ECMOHO Limited (NASDAQ: MOHO) jumped 67% to $0.3890 after jumping 10% on Tuesday. Nordstrom, Inc. (NYSE: JWN) shares jumped 38.7% to $27.11 after the company reported... 
Via Benzinga
Earnings Scheduled For March 1, 2022
Companies Reporting Before The Bell • Precigen (NASDAQ:PGEN) is expected to report earnings for its fourth quarter. • TG Therapeutics (NASDAQ:TGTX) is estimated... 
Via Benzinga
68 Biggest Movers From Yesterday
Gainers ECMOHO Limited (NASDAQ: MOHO) climbed 56.7% to close at $0.3650 on Wednesday after jumping 10% on Tuesday. Imperial Petroleum Inc. (NASDAQ: IMPP) shares jumped 39.2% to... 
Via Benzinga
Lab Study Shows Inovio's COVID-19 Vaccine Candidate Weaker Against Omicron Variant
Tucked in the Q4 earnings release, Inovio Pharmaceuticals Inc (NASDAQ: INO) has paused enrollment for an ongoing INNOVATE Phase 3 trial of its lead COVID-19 vaccine... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers IsoPlexis (NASDAQ:ISO) shares moved upwards by 22.8% to $5.5 during Wednesday's pre-market session. The company's market cap stands at $214.2 million. The... 
Via Benzinga
The Daily Biotech Pulse: Karyopharm Flags Delay In Selinexor Label Expansion, Finch, Celyad Hit With Clinical Holds, Adagene Strikes R&D Collaboration With Sanofi
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Karyopharm Says FDA Mandates Additional Study For Expanding Selinexor Label... 
Via Benzinga
28 Stocks Moving in Wednesday's Pre-Market Session
Gainers Guardion Health Sciences, Inc. (NASDAQ: GHSI) rose 46.4% to $0.4098 in pre-market trading after jumping around 48% on Tuesday. Guardion Health Sciences recently reported... 
Via Benzinga
Inovio Pharmaceuticals: Q4 Earnings Insights
Inovio Pharmaceuticals (NASDAQ:INO) reported its Q4 earnings results on Tuesday, March 1, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Organogenesis Holdings (NASDAQ:ORGO 
Via Benzinga
The Daily Biotech Pulse: Legend Biotech, CTI Biopharma Receive FDA Approvals, AbbVie Announces Delay In Skyrizi Review, Editas Gains On CRISPR Patent Resolution
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Editas Gains On Resolution Of CRISPR Gene Editing Patent Case Editas Medicine... 
Via Benzinga
The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight
Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first... 
Via Benzinga
Thinking About Buying Stock In AMC Entertainment, Romeo Power Or Inovio Pharmaceuticals?
Analysts and brokerage firms often use ratings when they issue stock recommendations to stock traders. Analysts arrive at stock ratings b... 
Via Benzinga
Why This Analyst Has Increased Confidence In Inovio Pharmaceuticals
Following the recent pullback in Inovio Pharmaceuticals Inc.’s (NASDAQ: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 21, 2022
Upgrades According to Seaport Global, the prior rating for KB Home (NYSE: 
Via Benzinga
10 Biggest Price Target Changes For Friday
Barclays cut Netflix, Inc. (NASDAQ: NFLX) price target from $675 to $425. Netflix shares fell 19.6% to $408.58 in pre-market trading. Keybanc cut Chipotle Mexican Grill, Inc... 
Via Benzinga
Growing Acceptance Of Digital Health Services is a Huge Boon for Healthcare Cloud Computing Market
Palm Beach, FL – January 20, 2022 – FinancialNewsMedia.com News Commentary – Cloud computing increases real-time data collection and improves accessibility to the data. It has outpaced the conventional... 
Via FinancialNewsMedia
Bill Gates Says Misinformation Related To Fauci, Himself Doesn't 'Make Sense,' Talks COVID-19 After Omicron
Microsoft Corporation (NASDAQ: MSFT) co-founder Bill Gates answered questions related to COVID-19 on Twitter Tuesday. What Happened: The questions to Gates were routed through... 
Via Benzinga
Stocks Hitting New 52-Week Lows Today
On Monday morning, 60 companies achieved new lows for the year. Points of Interest From Today's 52-Week Lows And Highs: Ginkgo Bioworks Holdings (NYSE:DNA) was... 
Via Benzinga
Wingstop, Akamai Initiations Among Today's Top Calls On Wall Street
Benchmark analyst Todd Brooks initiated coverage of Wingstop (WING) with a Hold rating and no price target. The analyst believes the stock's risk/reward is balanced at these levels given the current 
Via Talk Markets
If You Invested $1,000 In Inovio Stock One Year Ago, Here's How Much You'd Have Now
Investors who have owned stocks in the last year have generally experienced some big gains. In fact, the SPDR S&P 500 (NYSE: SPY) total return over the last 12 months is 29.2... 
Via Benzinga
Market Briefing For Thursday, Dec. 23
'Fortune favors the brave' it is said; it's partially so in this market, where we certainly got the ignition Tuesday of the seasonal rebound we looked for and more on Wednesday. 
Via Talk Markets
Why Jim Cramer Likes MGM Growth Properties
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Enterprise Products Partners L.P. (NYSE: 
Via Benzinga
Why You Should Buy Moderna Stock at Every Dip
Moderna’s cash growth will continue as demand for booster shots and vaccines for the omicron variant increase, giving a boost to MRNA stock. 
Via InvestorPlace
Here's Why These 3 COVID-19 Vaccine Stocks Got Crushed This Week
These second-tier COVID-19 vaccine players plunged due to fears about the potential impacts of the omicron variant. 
Via The Motley Fool
The 'Highly Mutated Virus' Signals A Need For Annual Shots: BioNTech CEO
The omicron variant signals a need for annual Covid shots, BioNTech's CEO said. 
Via Investor's Business Daily
2 Stocks That Are Down 60% (or More) From Their 52-Week Highs
One of these stocks is poised to rebound, but the other still looks very risky. 
Via The Motley Fool
Topics Economy
Adagio Continues Its Run As Biotech Stocks Moderna, BioNTech Dive On Omicron Threat
Biotech stocks diverged Tuesday with Adagio continuing a run on the potential for its antibody to target Covid's omicron variant. 
Via Investor's Business Daily
Vaccine Stocks Ask The Unthinkable: What Happens If Today's Covid Shots Fail?
Smaller companies are working on next-generation approaches to Covid treatment. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.